GlassScriptPhysician profile
Sonia T Orcutt
NPI 1750528543
$772.42
in general payments reported to CMS, 2019-2025
9 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.99 · 2020: $58.31 · 2021: $197 · 2022: $14.28 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $428.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Histosonics, INC. | $428.37 | 2025 | |
| Intuitive Surgical, INC. | $186.12 | 2021 | |
| Z-Medica, LLC | $59.04 | 2019 | |
| Bolder Surgical LLC | $21.10 | 2020-2021 | |
| Angiodynamics, INC. | $18.11 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $16.53 | 2020 | |
| Shire North American Group INC | $14.95 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.28 | 2022 | |
| Merck Sharp & Dohme LLC | $13.92 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Orcutt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.